source
- Argenx to acquire Forte Biosciences for $2.2 billion, bolstering its autoimmune drug pipelineArgenx announced it will purchase Dallas-based Forte Biosciences for $2.2 billion in cash. The transaction values Forte at $77 per share, a 41 percent premium to its closing price on Friday. The a…
- Sarepta Therapeutics appoints Michael Severino, former Tessera CEO, as new chief executiveSarepta Therapeutics announced that Michael Severino will become its chief executive, effective Tuesday. Severino previously led Tessera Therapeutics. He replaces Doug Ingram, who said he will ret…